NAD+ vs TB-500
Extensively Studied vs Well Studied
synergistic Complementary tissue regeneration effects
Molecular Data
NAD+ TB-500
Weight 663.43 Da 4,963.44 Da
Half-life 1-4 hours (intracellular) ~2 hours
Chain — 43 amino acids
Type Coenzyme Thymosin fragment
Key Benefits
NAD+
01 Restores mitochondrial function and ATP synthesis
02 Enhances glucose and fat metabolism
03 Improves oxygen utilization and endurance
04 Activates DNA repair mechanisms
05 Supports longevity pathways via sirtuins
06 Improves mental clarity and focus
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
NAD+
IV: 250-1000mg; IM/SubQ: 100-500mg; Intranasal: 25-50mg; Oral precursors: 100-500mg NMN/NR / IV: 1-2x weekly; IM/SubQ: 2-3x weekly; Intranasal: 1-2x daily; Oral: daily
IV Infusion 250-1000mg 1-2x weekly
IM/SubQ 100-500mg 2-3x weekly
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
NAD+
Mild flushing during IV infusion
Temporary nausea
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
IV administration requires medical supervision
Avoid alcohol during treatment
Maintain consistent dosing schedule
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
NAD+ TB-500
Status Extensively Studied Well Studied
References 4 studies 4 studies
Latest — March 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.